Drug Profile
Estradiol vaginal - Pfizer
Alternative Names: EstringLatest Information Update: 27 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Endo, Inc.; Pfizer
- Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Genitourinary disorders
Most Recent Events
- 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
- 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer